Viral hepatitis C and metabolic syndrome

Czech version

Authors: J. Stránský
Authors‘ workplace: Přednosta: prof. MUDr. Jiří Horák, CSc. ; I. interní klinika ; 3. lékařská fakulta ; Fakultní nemocnice Královské Vinohrady, Praha ; Univerzita Karlova v Praze
Published in: Prakt. Lék. 2010; 90(3): 148-152
Category: Reviews

Overview

This review article describes how to prevent the progression of chronic hepatitis C into liver fibrosis and cirrhosis in early stages of liver disease and, in the cases of non-responders, after combination treatment with pegylated interferon alpha and ribavirin. Possible risk factors such – as being

overweight,
obesity,
steatosis,
fibrosis, and
alcohol consumption

are evaluated.
The relationship between chronic hepatitis C, obesity, insulin resistance, diabetes mellitus and metabolic syndrome is presented. Finally, there are guidelines on how to improve the response to antiviral treatment with pegylated interferon alpha and ribavirin in patients who are overweight, have steatosis and insulin resistance through consistent treatment of metabolic syndrome.

Key words:
viral hepatitis C, obesity, steatosis, fibrosis, cirrhosis, insulin resistance, diabetes, metabolic syndrome.

Sources

1. Ghany, M.G., Strader, D.B., Thomas, D.L., Seef, L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology, 2009, 49, p. 1335-1374.

2. Kleiner, D.E. The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. Semin. Liv. Dis. 2005, 25, p. 52-64.

3. Pelikánová, T. Metabolický syndrom a hyperglykémie. Remedia. 2006, 16, 2, s. 153-158.

4. Sucharda, P. Obezita – součást nebo podmínka metabolického syndromu? Příloha Postgrad. Med. 2007, 9, 8, s. 42-46.

5. Stender, S., Dyerberg, J., Astrup, A. Fast food: unfriendly and unhealthy. Int. J. Obes. 2007, 31, p. 887-890.

6. Kechagias, S., Ernersson, A., Dahlqvist, O. et al. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut 2008, 57, p. 649-654.

7. Marchesini, G., Ridolfi, V., Nepoti, V. Hepatotoxicity of fast food? Gut 2008, 57, p. 568-570.

8. Pischon, T., Boeing, H., Hoffman, K. et al. General and abdominal adiposity and risk of death in Europe. N. Engl. J. Med. 2008, 359, p. 2105-2120.

9. Williams, C.L., Kimm, S.Y.S. Prevention and treatment of childhood obesity. Ann. NY Acad. Sci. 1993, 699, 303 p.

10. Weiss, R., Dziura, J., Burgert, T.S. et al. Obesity and the metabolic syndrome in children and adolescents. N. Engl. J. Med. 2004, 350, p. 2362-2374.

11. Negro, F. Overview of the mechanism of fatty liver induced by HCV. Abstracts of Falk Symposium 171, Hannover 2009, p. 80.

12. Fernández-Salazar, L.I., Álvarez-Gago, T., Aller de la Fuente, R. et al. Iron overload and genotype 3 are associated with liver steatosis in chronic hepatitis C. Rev. Esp. Enferm. Dig. 2004, 96, p. 818-828.

13. Monto, A., Alonzo, J., Watson J.J. et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002, 36, p. 729-736.

14. Powell, E.E., Ali, A., Clouston, A.D. et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 2005, 129, p. 1937-1943.

15. Solís Herruzo, J. A., Solís-Munoz, P. Iron, hepatitis C virus and hepatic steatosis. Rev. Esp. Enferm. Dig. 2004, 96, p. 809-814.

16. Hu, K.Q., Kyulo, N.L., Esrailian, E. et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J. Hepatol. 2004, 40, p. 147-154.

17. Ghany, M.G., Kleiner, D.E., Alter, H. et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003, 124, p. 97-104.

18. Ryder, S.D. Trent hepatitis C study group. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004, 53, p. 451-455.

19. D´Souza, R.F.C., Feakins, R., Mears, L. et al. Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 2005, 21, p. 519-524.

20. Serfaty, L., Poujol-Robert, A., Carbonell, N. et al. Effects of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Amer. J. Gastroenterol. 2002, 97, p. 1807-1812.

21. Shintani, Y., Fujie, H., Miyoshi, H. et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004, 126, p. 840-848.

22. Petta, S., Camma, C., Di Marco, V. D. et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotyp 1 HCV infection. Amer. J. Gastroenterol. 2008, 103, p. 1136-1144.

23. Sanyal, A.J., Contos, M.J., Sterling, R.K. et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Amer. J. Gastroenterol. 2003, 98, p. 2064-2071.

24. Nanda, K.S., Ryan, E.J., Murray, B.F. et al. Effect of chronic hepatitis C virus infection on bone disease in postmenopausal women. Clin. Gastroenterol. Hepatol. 2009, 7, p. 894-899.

25. The Expert Report Panel. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. World Cancer Research Fund and American Institute for Cancer Research. Washington, DC, 2007, 517 p.

26. Ohki, T., Tateishi, R., Sato, T. et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin. Gastroenterol. Hepatol. 2008, 6, p. 459-464.

27. Lok, A.S., Everhart, J.E., Chung, R.T. et al. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin. Gastroenterol. Hepatol. 2007, 5, p. 245-254.

28. Everhart, J.E., Lok, A.S., Kim, H.E. et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009, 137, p. 549-557.

29. Lok, A.S., Everhart, J.E., Chung, R.T. et al. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2009, 49, p. 1828-1837.

30. Hanouneh, I.A., Feldstein, A.E., Lopez, R. et al. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin. Gastroenterol. Hepatol. 2008, 6, p. 584-589.

31. Hickman, I.J., Clouston, A.D., Macdonald, G.A. et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51, p. 89-94.

32. Sacks, F.M., Bray, G.A., Carey, V.J. et al. Comparison of weight-loss diets with different composition of fat, protein, and carbohydrates. N. Engl. J. Med. 2009, 360, p. 859-873.

33. Katan, M.B. Weight-loss diets for the prevention and treatment of obesity. N. Engl. J. Med. 2009, 360, p. 923-925.